New cancer drug trial cut short after early testing

NCT ID NCT06488716

Terminated Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called RO7759065, alone or with another drug (atezolizumab), in 12 people with advanced solid tumors that could not be cured. The main goals were to check safety and how the drug moves through the body. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOUR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOUR

Contacts and locations

Locations

British Columbia Cancer Agency

Vancouver, British Columbia, V5Z 4R2, Canada
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Clinica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Clinica Universidad de Navarra-Madrid

Madrid, 28027, Spain
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2MR, Canada
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States
Sir Mortimer B Davis Jewish General Hospital-3755 Cote Sainte-Catherine

Montreal, Quebec, H3T 1E2, Canada
St Vincent's Hospital Sydney

Darlinghurst, New South Wales, 2010, Australia
Tennesse Oncology - NASH - SCRI - PPDS

Chattanooga, Tennessee, 37404-1130, United States
University of Colorado

Aurora, Colorado, 80045-2517, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.